Search results
Showing 1 to 15 of 17 results for isatuximab
Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.
NICE is unable to make a recommendation on isatuximab (Sarclisa) with carfilzomib (Kyprolis) and dexamethasone for treating relapsed or refractory multiple myeloma because Sanofi did not provide an evidence submission.
Show all sections
Sections for TA727
In development [GID-TA10912] Expected publication date: 16 July 2025
Technology appraisal and highly specialised technologies appeals
Technology appraisal and Highly specialised technologies appeals
In development [GID-TA11201] Expected publication date: 19 March 2025
In development [GID-TA11203] Expected publication date: 05 March 2025
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults.
In development [GID-TA10979] Expected publication date: TBC
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Awaiting development [GID-TA11465] Expected publication date: TBC
Evidence-based recommendations on Ixazomib (Ninlaro) with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.